Literature DB >> 11823721

Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data.

Vesna Sossi1, Raúl de La Fuente-Fernández, James E Holden, Doris J Doudet, Jess McKenzie, A J Stoessl, T J Ruth.   

Abstract

An increase in dopamine turnover has been hypothesized to occur early in Parkinson's disease (PD) as a compensatory mechanism for dopaminergic neuronal loss. A new approach to the determination of dopamine turnover was developed using 4-hour-long 18 F-fluorodopa (FD) positron emission tomography (PET) data. An effective dopamine turnover, an estimate of dopamine turnover, has been measured using its inverse, the effective dopamine distribution volume (EDV). This new method is based on a reversible tracer approach and determines the EDV using a graphical method. Six healthy subjects and 10 subjects with very early PD underwent a 4-hour-long FD scan. The EDV and the plasma uptake rate constant K(i), a marker of dopamine synthesis and storage, were compared according to their ability to separate the PD group from the healthy group. The EDV was the better discriminator (93.8% correct classification versus 81.3% for K(i)). Effective dopamine distribution volume decreased by 65% in the PD group relative to the healthy group, whereas the decrease in K(i) was 39%. These results show that changes in EDV are measurable with PET earlier than changes in the dopamine synthesis and storage rate, indicating that EDV is a sensitive marker for early PD and that a dopamine turnover increase likely serves as an early compensatory mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823721     DOI: 10.1097/00004647-200202000-00011

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  40 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 3.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

4.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

5.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

6.  Dual time point method for the quantification of irreversible tracer kinetics: A reference tissue approach applied to [18F]-FDOPA brain PET.

Authors:  I Lopes Alves; Sanne K Meles; Antoon Tm Willemsen; Rudi A Dierckx; Ana M Marques da Silva; Klaus L Leenders; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-19       Impact factor: 6.200

7.  Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.

Authors:  Catherine L Gallagher; Terrence R Oakes; Sterling C Johnson; Moo K Chung; James E Holden; Barbara B Bendlin; Donald G McLaren; Guofan Xu; Robert J Nickles; Robert Pyzalski; Onofre DeJesus; W Douglas Brown
Journal:  Mov Disord       Date:  2011-03-29       Impact factor: 10.338

8.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Patricia Sullivan; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2016-07-20       Impact factor: 4.891

Review 9.  Update on Molecular Imaging in Parkinson's Disease.

Authors:  Zhen-Yang Liu; Feng-Tao Liu; Chuan-Tao Zuo; James B Koprich; Jian Wang
Journal:  Neurosci Bull       Date:  2017-12-27       Impact factor: 5.203

10.  Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis.

Authors:  Ferogh A Ahmadi; Tom N Grammatopoulos; Andy M Poczobutt; Susan M Jones; Laurence D Snell; Mita Das; W Michael Zawada
Journal:  Neurochem Res       Date:  2007-11-10       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.